Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2019. The document serves as a transaction notification reporting share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions were executed on the London Stock Exchange (XLON) on January 10, 2019.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Type | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | £15.2440 | 385 shares |
Note: The total volume of 385 shares is the aggregate of individual transactions listed in the filing.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It documents routine share acquisitions resulting from the re-investment of dividends paid on January 10, 2019, under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is strictly a regulatory disclosure of insider share transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved 11 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and Company Secretary (Mrs V A Whyte).
- Share Price: The execution price for all transactions was uniform at £15.2440 per share.
- Volume Distribution: The largest individual acquisition was 73 shares (by Mr D S Redfern and Ms C Thomas), while the smallest was 3 shares (by Mr L Miels).
- Regulatory Context: This filing satisfies disclosure requirements under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.